Loading…
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $411M | $370M | $271M | $186M | 23.1% | 14.7% | 1059.2% |
| 2024 | $359M | $85M | $23M | $184M | 3.4% | 15.5% | -87.0% |
| 2023 | $310M | $235M | $180M | $141M | 26.6% | -6.3% | -16.0% |
| 2022 | $331M | $308M | $214M | $202M | 37.8% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 331.34 | 310.46 | 358.71 | 411.33 |
| Operating Revenue | - | 331.34 | 310.46 | 358.71 | 411.33 |
| Cost Of Revenue | - | 13.79 | 42.64 | 36.60 | 77.38 |
| Gross Profit | - | 317.55 | 267.82 | 322.11 | 333.94 |
| Operating Expense | - | 110.55 | 153.94 | 155.25 | 170.20 |
| Research And Development | - | 41.43 | 33.92 | 13.65 | 30.60 |
| Selling General And Administration | - | 63.54 | 98.23 | 115.69 | 113.32 |
| Total Expenses | - | 124.34 | 196.58 | 191.84 | 247.58 |
| Operating Income | - | 207 | 113.88 | 166.87 | 163.74 |
| Total Operating Income As Reported | - | -36.95 | 113.88 | 166.87 | 163.74 |
| EBITDA | - | 308.32 | 235.04 | 85.50 | 369.84 |
| Normalized EBITDA | - | 53.82 | 223.91 | 144.66 | 349.68 |
| EBIT | - | 302.74 | 213.26 | 59.60 | 343.56 |
| Interest Income | - | 6.37 | 15.82 | 19.14 | 21.09 |
| Interest Expense | - | 15.79 | 19.16 | 22.21 | 16.70 |
| Net Interest Income | - | -9.42 | -3.34 | -3.07 | 4.39 |
| Other Non Operating Income Expenses | - | -3.37 | -4.97 | -3 | -2.86 |
| Other Income Expense | - | 89.37 | 83.55 | -126.41 | 158.73 |
| Interest Income Non Operating | - | 6.37 | 15.82 | 19.14 | 21.09 |
| Interest Expense Non Operating | - | 15.79 | 19.16 | 22.21 | 16.70 |
| Net Non Operating Interest Income Expense | - | -9.42 | -3.34 | -3.07 | 4.39 |
| Pretax Income | - | 286.95 | 194.10 | 37.39 | 326.86 |
| Tax Provision | - | 66.69 | 14.38 | 14 | 55.70 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 59.14 | 0.82 | -22.19 | 3.43 |
| Net Income Continuous Operations | - | 220.26 | 179.72 | 23.39 | 271.17 |
| Net Income From Continuing And Discontinued Operation | - | 213.92 | 179.72 | 23.39 | 271.17 |
| Net Income From Continuing Operation Net Minority Interest | - | 213.92 | 179.72 | 23.39 | 271.17 |
| Net Income | - | 213.92 | 179.72 | 23.39 | 271.17 |
| Net Income Common Stockholders | - | 213.92 | 179.72 | 23.39 | 271.17 |
| Net Income Including Noncontrolling Interests | - | 220.26 | 179.72 | 23.39 | 271.17 |
| Normalized Income | - | 18.57 | 169.42 | 60.37 | 254.43 |
| Diluted NI Availto Com Stockholders | - | 225.57 | 191.30 | 26.86 | 279.82 |
| Basic Average Shares | - | 69.64 | 65.44 | 62.73 | 67.40 |
| Diluted Average Shares | - | 95.25 | 86.88 | 74.19 | 84.76 |
| Reconciled Depreciation | - | 5.58 | 21.78 | 25.90 | 26.28 |
| Reconciled Cost Of Revenue | - | 13.79 | 42.64 | 36.60 | 77.38 |
| Total Unusual Items | - | 254.50 | 11.13 | -59.16 | 20.16 |
| Total Unusual Items Excluding Goodwill | - | 254.50 | 11.13 | -59.16 | 20.16 |
| Minority Interests | -102.98 | -6.34 | 0 | 0 | - |
| Special Income Charges | 0 | 246.03 | 0 | 0 | - |
| Gain On Sale Of Business | 0 | 266.70 | 0 | 0 | - |
| Other Special Charges | -0.73 | 20.66 | - | - | - |
| Gain On Sale Of Security | - | 8.46 | 11.13 | -59.16 | 20.16 |
| Depreciation Amortization Depletion Income Statement | - | 5.58 | 21.78 | 25.90 | 26.28 |
| Depreciation And Amortization In Income Statement | - | 5.58 | 21.78 | 25.90 | 26.28 |
| General And Administrative Expense | 16.19 | 63.54 | - | - | - |
| Other Gand A | 16.19 | 63.54 | - | - | - |
| Earnings From Equity Interest | - | -161.75 | 77.39 | -64.25 | 141.43 |
| Average Dilution Earnings | - | 11.65 | 11.58 | 3.47 | 8.66 |
| Amortization | - | 5.58 | 21.78 | 25.90 | 26.28 |
| Amortization Of Intangibles Income Statement | - | 5.58 | 21.78 | 25.90 | 26.28 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Innoviva, Inc.this co. | INVA | $1.6B | 6.03 | 1.39 | 23.1% | 3.66 |
| Novavax, Inc. | NVAX | $1.7B | 3.81 | -13.12 | -344.7% | 3.42 |
| Addus HomeCare Corporation | ADUS | $1.7B | 17.46 | 1.54 | 8.8% | 11.20 |
| GeneDx Holdings Corp. | WGS | $1.7B | -79.47 | 5.42 | -6.8% | 138.20 |
| Palvella Therapeutics, Inc. | PVLA | $1.6B | -39.48 | 58.85 |
| - |
| - |
| - |
| - |
| -149.1% |
| -44.28 |
| Fortrea Holdings Inc. | FTRE | $1.6B | - | 2.90 | -175.0% | - |
| Capricor Therapeutics, Inc. | CAPR | $1.6B | -15.41 | 5.29 | -34.4% | -13.44 |
| Tyra Biosciences, Inc. | TYRA | $1.6B | -13.48 | 6.24 | -46.3% | -11.68 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.6B | -5.59 | 24.71 | -441.6% | -7.18 |
| Peer Median | - | -13.48 | 5.36 | -97.7% | -7.18 | |